EQS-News

    137 Aufrufe 137 0 Kommentare 0 Kommentare

    Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

    Für Sie zusammengefasst
    • Abivax congratulates Ambros and Ruvkun on Nobel Prize.
    • Their microRNA research advances gene regulation insights.
    • Abivax's obefazimod targets microRNA for inflammation relief.

    EQS-News: ABIVAX / Key word(s): Miscellaneous
    Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

    07.10.2024 / 22:01 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

    PARIS, France, October 7, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, is thrilled to extend heartfelt congratulations to Victor Ambros and Gary Ruvkun for being awarded the Nobel Prize in Physiology or Medicine. Their groundbreaking work in the field of microRNA has significantly advanced our understanding of gene regulation and its implications for human health.

    Marc de Garidel, CEO of Abivax, said, “The recognition of Ambros and Ruvkun underscores the importance of microRNA research and its potential to transform therapeutic approaches”. He went on to say “At Abivax, we are proud to be at the forefront of innovative therapies that harness the power of microRNAs. Our lead candidate, obefazimod, which is currently being evaluated in a Phase 3 Trial clinical program for Ulcerative Colitis and a Phase 2B Trial for Crohn’s Disease, acts by enhancing expression of microRNA-124 (miR-124), which stabilizes inflammatory pathways to reduce inflammation in patients with chronic inflammatory conditions.”

    Didier Scherrer, Chief Scientific Officer at Abivax, stated, “We look forward to further developing obefazimod and contributing to the evolving landscape of treatments for ulcerative colitis and Crohn's disease with a new mechanism of action, inspired by the pioneering work of luminaries like Victor Ambros and Gary Ruvkun.”

    About Obefazimod

    Obefazimod, Abivax’s lead investigational drug candidate, is an orally administered small molecule that was demonstrated to potentially enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with ulcerative colitis (UC) have generated positive data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022. A Phase 2b clinical trial in Crohn’s disease is ongoing, with the first patient enrolled in October 2024, and exploration of potential combination therapy opportunities in UC is ongoing.

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation 07.10.2024 / 22:01 CET/CEST The issuer is …